Gujarat Themis Biosyn Ltd · NSE:GUJTHEM
Gujarat Themis Biosyn — Q1 FY22 Earnings Presentation
27 slides from Gujarat Themis Biosyn's earnings presentation, September 2021
Slide 1: Gujarat Themis Biosyn Limited Investor Presentation
Gujarat Themis Biosyn Limited Investor Presentation September 2021
Slide 2: Disclaimer
Click to edit Master title style Disclaimer This presentation has been prepared by Gujarat Themis Biosyn Limited (the “Company” or “GTBL”) solely for information purposes and does not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form t
Slide 3: Contents
Click to editofMaster Table title style Contents Company Overview Business Overview Industry Overview Financial Highlights Way Ahead 3
Slide 4: Company Overview
Company Overview
Slide 5: Among India's few fermentation based intermediate manufacturers
Click Among to editIndia’s Master fewtitle style Fermentation based Intermediate manufacturers GTBL among one of India’s few fermentation based manufacturers in pharmaceutical field State of Art Manufacturing Facility ▪ Incorporated in 1981 as joint ▪ Plant in Vapi (Gujarat) sector Company with GIIC
Slide 6: Journey So Far
Click to edit Master Journey So Fartitle style ▪ BIFR declared GTBL as sick ▪ Repaid total Company working capital ▪ Established as joint ▪ Dr. Dinesh Patel stepped in as ▪ Production sector Company with loan ▪ Entered into JV agreement Guarantor and Adviser ▪ Deregistration continues Govt of Gujara
Slide 7: Expert and Experienced Management Team
Click to edit Master Expert title style Management Team and Experienced Dr. Dinesh Patel Dr. Sachin Patel Chairman Director ▪ Doctorate in Medicinal Chemistry ▪ Member of Royal Society of Chemistry, London, U.K. ▪ Doctorate in Biological chemistry from Christ's College, ▪ Industrialist having workin
Slide 8: Key Strengths
Click to Keyedit Master title style Strengths Strong Product Portfolio ▪ Demand side remains strong for product manufactured 01 by GTBL ▪ More than decade old products with no replacement for these ▪ Continued to be most accepted and preferred products Investments in R&D 02 with growing demand ▪ New
Slide 9: Business Overview
Business Overview
Slide 10: Strong & Niche Product Portfolio – Growing at pace
Click toStrong edit Master & Nichetitle style Portfolio – Growing at pace Product Current Product Portfolio Rifamycin ▪ Identified and working developing four ▪ An intermediate for Rifamycin S ▪ An intermediate for New Products and adding to portfolio manufacturing drug manufacturing drug O Rifampic
Slide 11: Advantages of using the Unique Fermentation Process
Advantages Click to of using edit Master title the styleUnique Fermentation Process Fermentation Process Fermentation Broth Solid / Liquid Lab Filtration Separation GTBL and Fermentation Technology - Strive to develop new fermentation culture: ▪ Fermentation is the core competency of Company Primary
Slide 12: State of Art Manufacturing Facilities at Vapi
Click to editofMaster State title style Art Manufacturing Facilities at Vapi Among very few companies in India with fermentation capabilities Environment Friendly & Sustainable Process Using Aerobic Bacteria for Fermentation 12
Slide 13: Industry Overview
Industry Overview
Slide 14: Pharmaceutical Market – An Overview
Click to edit Master title Pharmaceutical style An Overview Market- Active Pharmaceutical Ingredient Market valued at USD 172.69 Billion in 2018 and expected to reach North America-expected to dominate Active Global Market 01 02 USD 263.80 Billion by 2025 with CAGR of 6.24% over Pharmaceutical Ingre
Slide 15: The Indian Pharma Advantage
Click to Theedit Master Indian title style Pharma Advantage ▪ Low cost of production & R&D boosts efficiency of Indian pharma companies, leading to competitive exports Cost Efficiency 01 ▪ India’s cost of production is approximately 33 per cent lower than that of the US ▪ India’s ability to manufact
Slide 16: Q1 FY22 Financial Highlights
Q1 FY22 Financial Highlights
Slide 17: Q1 FY22 Financial Highlights
Click to Q1edit FY22Master titleHighlights Financial style Revenue (Rs. Cr) 32.44 26.35 27.20 24.40 23.30 15.66 Q4 FY20 Q1 FY21 Q2 FY21 Q3 FY21 Q4 FY21 Q1 FY22 EBITDA (Rs. Cr) / Margin (%) PAT (Rs. Cr) / Margin (%) 20 54.21% 60% 50.18% 51.55% 41.54% 18 14 35.58% 41.72% 39.84% 45% 16 42.08% 43.81% 50
Slide 18: Q1 FY22 Financial Highlights
Click to Q1edit FY22Master titleHighlights Financial style Rs. Crs Q1 FY22 Q1 FY21 YoY% Q4 FY21 Income from Operations 32.44 15.66 23.30 Other Operating Income 0.00 0.00 0.00 Total Income from Operations 32.44 15.66 107.12% 23.30 ▪ Revenue growth driven by Cost of Materials Consumed 5.87 4.74 0.82 c
Slide 19: Annual Financial Highlights
Annual Financial Highlights
Slide 20: Financial Highlights – FY21 vs FY20
Click to edit Master Financial title style Highlights – FY21 vs FY20 6.39% 26.67% 713 bps Revenue from Operations EBITDA EBITDA Margin Rs. 90.56 Crore Rs. 40.33 Crore 44.53% 27.48% 551 bps 27.42% PAT PAT Margin Basic EPS Rs. 30.18 Crore 33.32% Rs. 20.77 vs. Rs 16.30 FY20 20
Slide 21: Annual Financial Highlights – FY21
Click to edit Master Annual title Financial style Highlights – FY21 Revenue (Rs. Cr) 90.56 85.12 38.80 41.05 35.69 FY17 FY18 FY19 FY20 FY21 EBITDA (Rs. Cr) / Margin (%) PAT (Rs. Cr) / Margin (%) 45 44.5% 50% 37.4% 45% 33.3% 40 35 27.8% 35% 35 40% 30 30% 30 35% 30.2 30% 25 25% 25 17.9% 15.6% 16.1% 25
Slide 22: Key Ratios
Click to Keyedit Master title style Ratios RoCE(%)* RoA(%)** 37.0% 70.91% 34.2% 59.9% 42.77% 41.40% 20.4% 18.9% 19.6% 33.94% FY17 FY18 FY19 FY20 FY21 FY17 FY18 FY19 FY20 FY21 RoE(%)*** 53.3% 56.1% 43.2% 32.2% 34.6% FY17 FY18 FY19 FY20 FY21 ***RoE = Net Profit/Net Worth | **RoA = Net Profit/Average T
Slide 23: Annual Financial Highlights – FY21
Click to edit Master Annual title Financial style Highlights – FY21 Rs. Crs FY21 FY20 YoY% Income from Operations 90.56 85.12 Other Operating Income 0.00 0.00 ▪ Growth in revenue on Total Income from Operations 90.56 85.12 6.39% Cost of Materials Consumed 15.75 15.44 account of change in Changes In
Slide 24: Balance Sheet Highlights – As on 31st March 2021
Click to edit Master Balance Sheet title style – As on 31st March 2021 Highlights Rs. Cr. Rs. Cr. FY20 FY21 FY20 FY21 Total Equity & Liabilities Total Assets Shareholders Funds 42.20 69.95 Non Current Assets 34.94 24.94 Share Capital 7.26 7.26 Property Plant & Equipment 17.08 16.99 R&S 34.93 62.68 C
Slide 25: Way Ahead
c 7 Way Ahead
Slide 26: Our Way Ahead
Click to Ouredit WayMaster Ahead title style ▪ In process of identifying new products which have good domestic and export New Product Development & potential ▪ Company working on strategy to move up the value chain by way of forward Forward Integration integration into API ▪ New infrastructure being
Slide 27: Thank You
Click to edit You Thank Master title style For further information, please contact: Company : Investor Relations Advisors : Gujarat Themis Biosyn Limited Bridge Investor Relations Pvt. Ltd. Mr. Sangameshwar Iyer Mr. Amit Sharma - 9867726686 Mr. Rahul Trivedi - 9833541841 Sangameshwar.iyer@themismedi
Gujarat Themis Biosyn — Q1 FY22 Earnings Presentation on 6ix